SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The 56 Point TA; Charts With an Attitude -- Ignore unavailable to you. Want to Upgrade?


To: Doug R who wrote (22816)11/10/1998 12:14:00 PM
From: Redhead  Respond to of 79268
 
Doug,

Thanks....will hold off for a bit and watch it then.....

Smile

REd



To: Doug R who wrote (22816)11/12/1998 10:38:00 PM
From: Henry Niman  Respond to of 79268
 
On Monday, Ligand's topical Panretin will be up for review
before the FDA's oncologic advisory board. Approval is
widely expected (I expect a unanimous rec). Details are
linked to Ligand's Clinical Trials page at
biocognizance.com.